Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery

References

• Barchet TM, Amiji MM. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expet Opin Drug Deliv 2009;6:211–25
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokin 1996;30:463–81
   PubMed Web of Science ®Google Scholar
• Leenders KL, Poewe WH, Palmer AJ, et al. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986;20:258–62
   PubMed Web of Science ®Google Scholar
• Wade DN, Mearrick PT, Morris JL. Active transport of L-dopa in the intestine. Nature 1973;242:463–5
   PubMed Web of Science ®Google Scholar
• Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997–1005
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm Sci Technol Today 1999;2:49–59
   PubMedGoogle Scholar
• Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1–18
   PubMed Web of Science ®Google Scholar
• McMartin C, Hutchinson LE, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci 1987;76:535–40
   PubMed Web of Science ®Google Scholar
• Dahlin M, Jansson B, Bjork E. Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci 2001;14:75–80
   PubMed Web of Science ®Google Scholar
• Westin U, Piras E, Jansson B, et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 2005;24:565–73
   PubMed Web of Science ®Google Scholar
• Wu H, Hu K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expet Opin Drug Deliv 2008;5:1159–68
   PubMed Web of Science ®Google Scholar
• Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev 2002;54:135–47
   PubMed Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127:97–109
   PubMed Web of Science ®Google Scholar
• Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomed 2011;6:363–71
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Babbar AK, et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008;358:285–91
   PubMed Web of Science ®Google Scholar
• Vyas TK, Babbar AK, Sharma RK, Misra A. Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J Drug Target 2005;13:317–24
   PubMed Web of Science ®Google Scholar
• Desai S, Vidyasagar G, Shah V, Desai D. Preparation and in vitro characterisation of mucoadhesive microspheres of midazolam: nose to brain administration. Asian J Pharm Clin Res 2011;4:100–2
   Google Scholar
• Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech 2006;7:E1--E7
   PubMed Web of Science ®Google Scholar
• Bhavna SV, Ali M, Baboota S, Ali J. Preparation and characterization of chitosan nanoparticles for nose to brain delivery of a cholinesterase inhibitor. Indian J Pharm Sci 2007;69:712–13
   Google Scholar
• Fazil M, Md S, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012;47:6–15
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol 2000;5:77–85
   PubMed Web of Science ®Google Scholar
• Smith JM, Dornish M, Wood EJ. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials 2005;26:3269–76
   PubMed Web of Science ®Google Scholar
• Kim S, Kim JH, Jeon O, et al. Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm 2009;71:420–30
   PubMed Web of Science ®Google Scholar
• Bhardwaj R, Blanchard J. Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407. J Pharm Sci 1996;85:915–19
   PubMed Web of Science ®Google Scholar
• Wang PL, Johnston TP. Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407. J Parenter Sci Technol 1993;47:183–9
   PubMedGoogle Scholar
• Katakam M, Bell LN, Banga AK. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 1995;84:713–16
   PubMed Web of Science ®Google Scholar
• Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloid Surf B, Biointerf 2012;90:21–7
   PubMed Web of Science ®Google Scholar
• Schmolka IR. Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res 1972;6:571–82
   PubMed Web of Science ®Google Scholar
• Gilbert JC, Richardson JL, Davies MC, et al. The effect of solutes and polymers on the gelation properties of pluronic F-127 solutions for controlled drug delivery. J Control Release 1987;5:113–18
   Google Scholar
• Choi HG, Oh YK, Kim C. In-situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int J Pharm 1998;165:23–32
   Web of Science ®Google Scholar
• Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008;70:735–40
   PubMed Web of Science ®Google Scholar
• Escobar-Chávez JJ, López-Cervantes M, Naïk A, et al. Applications of thermoreversible Pluronic F-127 gels in pharmaceutical formulations. J Pharm Pharmaceut Sci 2006;9:339–58
   PubMed Web of Science ®Google Scholar
• Vadnere M, Amidon G, Haslam JL. Thermodynamics studies on gel-sol transition of some pluronic polyols. Int J Pharm 1984;22:207–18
   Web of Science ®Google Scholar
• Hirai S, Yashike T, Mima H. Mechanism for the enhancement of the nasal absoption of insulin by surfactants. Int J Pharm 1978;9:173–8
   Google Scholar
• Pisal S, Reddy P, Paradkar A, et al. Nasal melatonin gels using pluronic PF-127 for chronobiological treatment of sleep disorder. Ind J Biotech 2004;3:369–77
   Google Scholar
• Gratieri T, Gelfuso GM, Rocha EM, et al. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010;75:186–93
   PubMed Web of Science ®Google Scholar
• Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 2009;1788:892–910
   PubMed Web of Science ®Google Scholar
• De Lorenzo AJ. Electron microscopy of the olfactory and gustatory pathways. Ann Otol Rhinol Laryngol 1960;69:410–20
   PubMedGoogle Scholar
• Oberdorster G, Sharp Z, Atudorei V, et al. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 2004;16:437–45
   PubMed Web of Science ®Google Scholar